189 related articles for article (PubMed ID: 34419018)
1. Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B.
Sprinzl MF; Feist C; Koch S; Kremer WM; Lackner KJ; Weinmann A; Galle PR
BMC Health Serv Res; 2021 Aug; 21(1):846. PubMed ID: 34419018
[TBL] [Abstract][Full Text] [Related]
2. Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment.
Gokcen P; Guzelbulut F; Adali G; Degirmenci Salturk AG; Ozturk O; Bahadir O; Kanatsiz E; Kiyak M; Ozdil K; Doganay HL
World J Gastroenterol; 2022 Feb; 28(6):665-674. PubMed ID: 35317422
[TBL] [Abstract][Full Text] [Related]
3. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.
Kim SU; Seo YS; Lee HA; Kim MN; Lee EJ; Shin HJ; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
Cancer Epidemiol Biomarkers Prev; 2020 Apr; 29(4):832-837. PubMed ID: 31988073
[TBL] [Abstract][Full Text] [Related]
5. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China.
Lou T; Li B; Xiong P; Jin C; Chen Y
J Viral Hepat; 2021 Oct; 28(10):1373-1380. PubMed ID: 34218498
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
7. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
Patmore LA; van Eekhout KMA; Buti M; Koc ÖM; Agarwal K; de Knegt RJ; Janssen HLA; van der Valk M; Lieveld FI; Hansen BE; Kramer M; de Bruijne J; Claassen MAA; Smit C; de Man RA; Takkenberg B; Carey I; Sonneveld MJ;
J Hepatol; 2024 Feb; 80(2):243-250. PubMed ID: 37898348
[TBL] [Abstract][Full Text] [Related]
9. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
Papatheodoridis G; Dalekos G; Sypsa V; Yurdaydin C; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Mangia G; Gatselis N; Keskin O; Savvidou S; de la Revilla J; Hansen BE; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
J Hepatol; 2016 Apr; 64(4):800-6. PubMed ID: 26678008
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M
Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526
[TBL] [Abstract][Full Text] [Related]
11. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
[TBL] [Abstract][Full Text] [Related]
12. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
13. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
[TBL] [Abstract][Full Text] [Related]
14. Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B.
Kamalapirat T; Yingcharoen K; Ungtrakul T; Soonklang K; Dechma J; Chunnuan P; Kusuman P; Pothijaroen C; Tawpa J; Cheirsilpa K; Auewarakul C
J Viral Hepat; 2021 Jul; 28(7):1034-1041. PubMed ID: 33880807
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B.
Voulgaris T; Papatheodoridi M; Lampertico P; Papatheodoridis GV
Liver Int; 2020 Mar; 40(3):484-495. PubMed ID: 31884726
[TBL] [Abstract][Full Text] [Related]
16. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B.
Sachar Y; Brahmania M; Dhanasekaran R; Congly SE
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372524
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.
Ungtrakul T; Mahidol C; Chun-On P; Laohapand C; Siripongsakun S; Worakitsitisatorn A; Vidhayakorn S; Boonchuay W; Dechma J; Sornsamdang G; Soonklang K; Sriprayoon T; Tanwandee T; Auewarakul CU
World J Gastroenterol; 2016 Sep; 22(34):7806-12. PubMed ID: 27678364
[TBL] [Abstract][Full Text] [Related]
18. Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center.
Demir M; Nigemeier J; Kütting F; Bowe A; Schramm C; Hoffmann V; Waldschmidt D; Goeser T; Steffen HM
Infection; 2015 Apr; 43(2):153-62. PubMed ID: 25701223
[TBL] [Abstract][Full Text] [Related]
19. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy.
Wong GL; Wong VW
World J Gastroenterol; 2013 Oct; 19(39):6515-22. PubMed ID: 24151375
[TBL] [Abstract][Full Text] [Related]
20. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
